弥漫大B细胞淋巴瘤患者预后的影响因素分析  

Analysis on Influencing Factors for Prognosis of Patients with Diffuse Large B-Cell Lymphoma

作　　者：吴春农[1] Wu Chunnong(Department of Hematology,The First People's Hospital of Liangshan Yi Autonomous Prefecture,Liangshan Yi Autonomous Prefecture 615000,Sichuan Province,China)

机构地区：[1]凉山彝族自治州第一人民医院血液科,四川凉山彝族自治州615000

出　　处：《中国社区医师》2024年第18期26-28,共3页Chinese Community Doctors

基　　金：凉山州学术和技术带头人培养资金资助项目,编号:【2023】5号。

摘　　要：目的:分析弥漫大B细胞淋巴瘤(DLBCL)患者预后的影响因素。方法:选取2018年1月—2021年1月凉山彝族自治州第一人民医院收治的DLBCL患者127例作为研究对象。统计患者预后结果,比较患者相关资料,分析DLBCL患者预后的影响因素。结果:随访2年,127例DLBCL患者存活92例(72.44%),死亡35例(27.56%),分别纳入存活组和死亡组。死亡组合并症>2种、结外器官受累数量≥2处、骨髓受累、Ann Arbor分期Ⅲ~Ⅳ期、化疗后未达完全缓解占比高于存活组,差异有统计学意义(P<0.05)。合并症>2种、结外器官受累数量≥2处、骨髓受累、Ann Arbor分期Ⅲ~Ⅳ期、化疗后未达完全缓解为DLBCL患者预后的独立危险因素(P<0.05)。结论:影响DLBCL患者预后的因素较为复杂,临床应采取针对性的应对措施改善患者预后。Objective:To analyze the influencing factors for prognosis of patients with diffuse large B-cell lymphoma(DLBCL).Methods:A total of 127 patients with DLBCL admitted to the First People's Hospital of Liangshan Yi Autonomous Prefecture from January 2018 to January 2021 were selected as the study subjects.The prognosis outcome of patients was counted.The relevant data of patients were compared.The influencing factors for the prognosis of patients with DLBCL were analyzed.Results:After 2 years of follow-up,92 cases(72.44%)of 127 patients with DLBCL survived and 35 cases(27.56%)died,and they were included in the survival group and the death group,respectively.The proportions of>2 complications,≥2 extranodal organ involvements,bone marrow involvement,Ann Arbor stage III-IV,and failure to achieve complete response after chemotherapy in the death group were higher than those in the survival group,and the difference was statistically significant(P<0.05).>2 complications,≥2 extranodal organ involvements,bone marrow involvement,Ann Arbor stage III-IV,and failure to achieve complete response after chemotherapy were independent risk factors for the prognosis of patients with DLBCL(P<0.05).Conclusion:The factors affecting the prognosis of patients with DLBCL are complex,and targeted countermeasures should be taken in clinical practice to improve the prognosis of patients.

关 键 词：弥漫大B细胞淋巴瘤 预后 化疗 

分 类 号：R733.1[医药卫生—肿瘤]